Bristol-Myers Squibb (NYSE: BMY) reported Q4 EPS of $1.67, $0.20 better than the analyst estimate of $1.47. Revenue for the quarter came in at $12.34 billion versus the consensus estimate of $11.54 billion.

GUIDANCE:

Bristol-Myers Squibb sees FY2025 EPS of $6.55-$6.85, versus the consensus of $6.92. Bristol-Myers Squibb sees FY2025 revenue of $45.5 billion, versus the consensus of $46.27 billion.

For earnings history and earnings-related data on Bristol-Myers Squibb (BMY) click here.